Granted Patent
B2
US 12,403,129 · App. 17/523,160 · Granted Sep 2, 2025
Isotope-enriched 3-amino-1-propanesulfonic acid derivatives for the treatment of cerebrovascular disease
Inventors:
Jiasheng Lu (Shanghai, CN); Jiamin Gu (Suzhou, CN); Xianqi Kong (Dollard-des-Ormeaux, CA)
Assignee:
RISEN (SUZHOU) PHARMA TECH CO., LTD.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
There are provided methods for treating or preventing a cerebrovascular disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an isotope-enriched compound or a pharmaceutical composition thereof, where the isotope-enriched compound has the general Formula (I) or is a pharmaceutically acceptable salt or ester thereof: R 1 R 2 X—CR 2 —CH 2 —CH 2 —SO 3 H (I).
Claims (9)
1. A method for treating cognitive impairment, for delaying or slowing the progression of said cognitive impairment, or for reducing the rate of decline of cognitive function, in a subject having or at risk of having said cognitive impairment or decline of cognitive function, the method comprising administering to said subject a therapeutically effective amount of an isotope-enriched compound, wherein the cognitive impairment or decline of cognitive function is caused by cerebrovascular disease, vascular dementia, stroke, global cerebral ischemia, or hypoxia and is not amyloid-β related, wherein the isotope-enriched compound has the general Formula (I) or a pharmaceutically acceptable salt or ester thereof:
R 1 R 2 X—CR 2 —CH 2 —CH 2 —SO 3 H (I)
where:
R 1 and R 2 are independently a hydrogen of natural abundance or a protecting group which have natural abundance or isotope enriched carbon and/or oxygen, said protecting group being selected from acyl, thiocarbonyl, and carbamoyl groups;
R is a hydrogen of natural abundance, or a deuterium (D), or a combination thereof; and
X is a nitrogen of natural abundance or 15 N, or a combination thereof;
provided that at least one of X, R, R 1 and R 2 comprises an atom that is not of natural abundance.
2. The method of claim 1 , wherein the isotope-enriched compound is:
or a pharmaceutically acceptable salt or ester thereof.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 22, 2022
From: LU, JIASHENG; GU, JIAMIN; KONG, XIANQI
To: RISEN (SUZHOU) PHARMA TECH CO., LTD.
Reel/Frame 059340/0866 →
Continuity (1)
References Cited (164)
US 5840294A
· Kisilevsky et al.
· 1998
[cited by applicant]
US 5972328A
· Kisilevsky et al.
· 1999
[cited by applicant]
US 6310073B1
· Kisilevsky et al.
· 2001
[cited by applicant]
US 6603008B1
· Ando et al.
· 2003
[cited by applicant]
US 6670399B2
· Green et al.
· 2003
[cited by applicant]
US 7253306B2
· Kong et al.
· 2007
[cited by applicant]
US 7414076B2
· Kong et al.
· 2008
[cited by applicant]
US 7517990B2
· Ito et al.
· 2009
[cited by applicant]
US 7851641B2
· Findeis
· 2010
[cited by applicant]
US 8044100B2
· Kong et al.
· 2011
[cited by applicant]
US 8304435B2
· Czarnik
· 2012
[cited by applicant]
US 8557994B2
· Dhanoa
· 2013
[cited by applicant]
US 8642801B2
· Kong et al.
· 2014
[cited by applicant]
US 8669275B2
· Czarnik
· 2014
[cited by applicant]
US 8748656B2
· Kong et al.
· 2014
[cited by applicant]
US 8835500B2
· Laurin et al.
· 2014
[cited by applicant]
US 8835654B2
· Kong et al.
· 2014
[cited by applicant]
US 8927553B2
· Dhanoa
· 2015
[cited by applicant]
US 9249149B2
· Silverman et al.
· 2016
[cited by applicant]
US 9453027B2
· Dhanoa
· 2016
[cited by applicant]
US 9464066B2
· Gopal
· 2016
[cited by applicant]
US 9499480B2
· Kong et al.
· 2016
[cited by applicant]
US 9980937B2
· Iwata et al.
· 2018
[cited by applicant]
US 20060079578A1
· Laurin et al.
· 2006
[cited by applicant]
US 20090076167A1
· Czarnik
· 2009
[cited by applicant]
US 20100120744A1
· Gant
· 2010
[cited by applicant]
US 20120214745A1
· Naicker et al.
· 2012
[cited by applicant]
US 20160331721A1
· Pan et al.
· 2016
[cited by applicant]
US 20190365771A1
· Lichenstein et al.
· 2019
[cited by applicant]
US 20200338040A1
· Elmaleh
· 2020
[cited by applicant]
US 20230295079A1
· Lu
· 2023
[cited by examiner]
CN 100528840
· 2009
[cited by applicant]
CN 101600730
· 2009
[cited by applicant]
CN 102793694A
· 2012
[cited by applicant]
CN 104781240
· 2015
[cited by applicant]
CN 108623501A
· 2018
[cited by applicant]
CN 112791078A
· 2021
[cited by applicant]
JP 2010514674A
· 2010
[cited by applicant]
WO 1994022437
· 1994
[cited by applicant]
WO 1996028187
· 1996
[cited by applicant]
WO 2009019534
· 2009
[cited by applicant]
WO 2015143447
· 2015
[cited by applicant]
WO 2016182812
· 2016
[cited by applicant]
WO 201727582
· 2017
[cited by applicant]
WO 2017044840
· 2017
[cited by applicant]
WO 2017055540
· 2017
[cited by applicant]
WO 2018170590A1
· 2018
[cited by applicant]
“Accompany.” Merriam-Webster.com Dictionary, Merriam-Webster, https://www.merriam-webster.com/dictionary/accompany. Accessed Nov. 1, 2023. (Year: 2023).
[cited by examiner]
Marchant, N., et al., “Cerebrovascular disease, beta-amyloid, and cognition in aging”, Neurobiology of Aging (2012), 33: 1006.e25-1006.e36. (Year: 2011).
[cited by examiner]
Lednicer, D (2008). The Organic Chemistry of Drug Synthesis (7th ed.). Hoboken: John Wiley & Sons. p. 15. ISBN 978-0-470-18066-2. (Year: 2008).
[cited by examiner]
Elsevier. “Age-related GABA decline is associated with poor cognition”. Medical press (Jan. 17, 2017), pp. 1-3, retrieved Aug. 29, 2024 from https://medicalxpress.com/news/2017-01-age-related-gabadecline-poor-cognition.…
[cited by examiner]
Russak, E.M. et al., Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals, Annals of Pharmacotherapy, Feb. 2019, 53(2), 211-216.
[cited by applicant]
Kaur, S. et al., Deuteration as a tool for optimization of metabolic stability and toxicity of drugs, Global Journal of Pharmacy & Pharmaceutical Sciences, Mar. 2017, 1(4), 555566.
[cited by applicant]
International Search Report and Written Opinion issued in co-pending International application No. PCT/CA2021/051600 on Jan. 18, 2022.
[cited by applicant]
Briggs et al., Clinical Medicine, 16(3):247-253 (2016), Exhibit 2005 for Inter Partes Review No. IPR2021-00347, Apr. 15, 2021.
[cited by applicant]
Cummings et al., Alzheimer's & Dementia, 2(4):222-232 (2016), Exhibit 2006 for Inter Partes Review No. IPR2021-00347, Apr. 15, 2021.
[cited by applicant]
Godyn et al., Pharmacological Reports, 68(1):127-38 (2015), Exhibit 2007 for Inter Partes Review No. IPR2021-00347, Apr. 15, 2021.
[cited by applicant]
Tofthagen, J. of the Advanced Practitioners in Oncology, 3(3):181-183 (2012), Exhibit 2025 for Inter Partes Review No. IPR2021-00347, Apr. 15, 2021.
[cited by applicant]
Rothwell, Lancet, 356(9454):176-86 (2005), Exhibit 2028 for Inter Partes Review No. IPR2021-00347, Apr. 15, 2021.
[cited by applicant]
Fisher et al., Curr Opin Drug Discov Devel, 9(1):101-9 (2006), Exhibit 2050 for Inter Partes Review No. IPR2021-00347, Oct. 6, 2021.
[cited by applicant]
Paper No. 36 for the Inter Partes Review, Petitioner's second updated exhibit list, Mar. 3, 2022.
[cited by applicant]
O'Brien, J.T. et al., Non-Alzheimer's dementia 3, Vascular dementia, The Lancet, vol. 386, pp. 1698-1706, Oct. 24, 2015.
[cited by applicant]
Petition for Inter Partes Review of U.S. Pat. No. 10,472,323, Inter Pates Review No. IPR2021-00347, Dec. 18, 2020.
[cited by applicant]
Exhibit 1002 for Inter Partes Review, Declartation of F. Peter Guengerich, Ph. D(2020).
[cited by applicant]
Exhibit 1010 for Inter Partes Review, P. Atkins et al., Chemical Principles, Third Edition (2005).
[cited by applicant]
Exhibit 1012 for Inter Partes Review, Morgan et al., “Old drugs yield new discoveries: Examples from the Prodrug, Chiral Switch, and site-selective deuteration strategies” in Barratt and Frail, Drug Repositiong: Bringin…
[cited by applicant]
Exhibit 1013 for Inter Partes Review, L.E. Dyck et al., “Effects of deuterium substitution on the catabolismof β-Phenylethylamine: An in vivo study”, J. Neurochemistry, 46:2, 399-404, 399 (1986).
[cited by applicant]
Exhibit 1018 for Inter Partes Review, T.R. Browne, ed., Stable Isotopes in Pharmaceutical Research (1997).
[cited by applicant]
Exhibit 1019 for Inter Partes REview, V.E. Anderson, “Isotope effects on enzyme-catalyzed reactions”, Current Opinion in Structural Biology, 2:757-764 (1992).
[cited by applicant]
Exhibit 1020 for Inter Partes Review, C. Hennig et al., “Secondary kinetic isotope effect in nucleophilic substitution”, J. Phys. Chem. A, 110:3071-79 (2006).
[cited by applicant]
Exhibit 1022 for Inter Partes Review, J. Belleau et al., “Effect of deuterium substitution in sympathomimetic amines on adrenergic responses”, Science 133:102-104 (1961).
[cited by applicant]
Exhibit 1024 for Inter Partes Review, J. Qui et al., “A new class of conformationally rigid analogues of 4-amino-5-nalopentanoic acids, potent inactivators of y-aminobutyric acird aminotransferase”, J. Med. Chem, 43706-…
[cited by applicant]
Exhibit 1025for Inter Partes Review, J. Mayer et al., “Homotaurine Metabolized to 3-Sulfopropanoate in Cupriavidus necator H16.” J. Bacteriology, 191:6052-6058 (2009).
[cited by applicant]
Exhibit 1021 for Inter Partes Review, O'Leary, “Multiple Isotope Effects on Enzyme-Catalyzed Reactions,” Annu. Rev. Biochem., 58:377-401 (1989).
[cited by applicant]
Exhibit 1023 for Inter Partes Review, Caldwell, J., et al., “An Introduction to Drug Disposition: the Basic Principles of Absorption, Distribution, Metabolism, and Excretion,” Toxic Pathology, 23(2), 102-114, 110 (1995).
[cited by applicant]
Exhibit 1026 for Inter Partes Review, T.S. Soper, et al., “Different Modes of Action of Inhibitors of Bacterial D-Amino Acid Transaminase.” J. Biol. Chem., 256:4263-68 (1981).
[cited by applicant]
Exhibit 1028 for Inter Partes Review, Yu et al., “Stereospecific Deuterium Substitution at the α-Carbon Position of Dopamine,” Biochemical Pharmacology, 35:1027-36 (1986).
[cited by applicant]
Exhibit 1031 for Inter Partes Review, Guengerich, F. P., “Kinetic deuterium isotope effects in cytochrome P450 reactions,” Methods in Enzymology, vol. 596, Chap. 9, pp. 217-238 (2017).
[cited by applicant]
Exhibit 1034 for Inter Partes Review, R. I. Feldman and H Weiner, “Horse Liver Aldehyde Dehydrogenase,” J. Biol. Chem. 247 (1), 267-272 (1972).
[cited by applicant]
Exhibit 1027 for Inter Partes Review, G. Burnett et al., “Mechanism-based Inaction of Pig Heart LAlanine Transaminase by L-Propargylglcine,” J. Biol. Chem., 255:3487-3497 (1980).
[cited by applicant]
Exhibit 1029 for Inter Partes Review, P.H. Yu, “Deuterium Isotope Effect in γ-Aminobutyric Acid Transamination,” J. Neurochemistry, 48:440-446, 443 (1987).
[cited by applicant]
Exhibit 1030 for Inter Partes Review, M.A. Rishavy, et al., “13C and 15N Kinetic Isotope Effects on the Reaction of Aspartate Aminotransferase,” Biochemistry, 27:7546-51 (2000).
[cited by applicant]
Exhibit 1032 for Inter Partes Review, C. Walsh, Enzymatic Reaction Mechanisms, Freeman, New York, pp. 796-797, (1979).
[cited by applicant]
Exhibit 1033 for Inter Partes Review, Miller et al., “Structure-Activity Relationships in the Oxidation of Para-Substituted Benzylamine Analogues by Recombinant Human Liver Monoamine Oxidase.” Biochemistry 38:41, 13670-…
[cited by applicant]
Exhibit 1035 for Inter Partes Review, B. Yoval-Sánchez et al., “New insights into the half-of-the-sites reactivity of human aldehyde dehydrogenase 1A1,” Proteins 81 (8), 1330-1339 (2013).
[cited by applicant]
Exhibit 1036 for Inter Partes Review, Guengerich, F. P., “Cytochrome P450 and Chemical Toxicology,” Chem. Res. Toxicol. 2008, 21, 1, 70-83.
[cited by applicant]
Exhibit 1037 for Inter Partes Review, Alzheon Press Release, “Alzheon Presents Positive Results of ALZ-801 Clinical Studies that Lead to Advancement to Pivotal Phase 3 Study in Alzheimer's Patients with APOE4/4” (Jul. 2…
[cited by applicant]
Exhibit 1014 for Inter Partes Review, Anslyn, et al. Modern Physical Organic Chemistry (2006).
[cited by applicant]
Exhibit 1011 for Inter Partes Review, CRC Handbook of Chemistry and Physics, 95th Edition (2015).
[cited by applicant]
Shoo, L. et al., The kinetic isotope effect in the search for deuterated drugs, Drug News & Perpectives 2010, 23(6), 398-404.
[cited by applicant]
Foster, A.B., Deuterieum isotope effects in the metabolism of drugs and xenobiotics: Implications for drug design, Advances in Drug Research, vol. 14, 1985.
[cited by applicant]
Cecil Textbook of Medecine, 20th edition (1196), vol. 2, pp. 2050-2057.
[cited by applicant]
Cecil Textbook of Medecine, 20th edition (1996), vol. 2, pp. 1992-1996.
[cited by applicant]
FDA mulls drugs to slow late-stage Alzheimer's [online], retrieved on Sep. 23, 2003 from the Internet, URL: http://www.cnn.com/2003/HEALTH/conditions/09/24/Alzheimers.drug.ap/index.html.
[cited by applicant]
Courtyn, J. et al., Synthesis of 11C-labelled acamprosate for PET studies, J. Labelled Cpd. Radiopharm, 2001, vol. 44, pp. 643-651.
[cited by applicant]
Zornoza, T. et al., Evidence of a flip-flop phenomenon in acamprosate pharmacokinetics: an in vivo study in rats, Biopharm, Drug Dispos., 2006, vol. 27, pp. 305-311.
[cited by applicant]
Zornoza, T. et al., Disposition of acamprosate in the rat: Influence of probenecid, Biopharm. Drug Dispos., 2002, vol. 23, pp. 283-291.
[cited by applicant]
Saivin, S. et al., Clinical Pharmacokinetics of Acamprosate, Clin. Pharmacokinet., 1998, vol. 35, pp. 331-345.
[cited by applicant]
Chabenat, C. et al., Physicochemical, pharmacological and pharmacokinetic study of a new GABAergic compound, calcium acetylhomotaurinate, Methods and Findings in Experimental and Clinical Pharmacology, 1998, vol. 10, pp…
[cited by applicant]
Buteau, Kristen C., “Deuterated Drugs: Unexpectedly nonobvious?”, 10 J. High Tech. L. 22, 2009, 22-74.
[cited by applicant]
Timmins, Graham S., “Deuterated Drugs : where are we now?”. Expert Opin Ther Pat. Oct. 2014; 24(10): 1067-1075.
[cited by applicant]
Decision Granting Institution of Inter Partes Review, Inter Partes Review No. IPR2021-00347, Jul. 14, 2021.
[cited by applicant]
Patent Owner Response, Inter Partes Review No. IPR2021-00347, Oct. 6, 2021.
[cited by applicant]
Declaration of Jonathan L. Sessler, Ph.D., Exhibit 2042 for Inter Partes Review No. IPR2021-00347, Oct. 6, 2021.
[cited by applicant]
Declaration of Steven L. Wagner, Ph.D., Exhibit 2068 for Inter Partes Review No. IPR2021-00347, Oct. 6, 2021.
[cited by applicant]
Rowley et al., J Med Chem, 40(25):4053-68 (1997), Exhibit 2096 for Inter Partes Review No. IPR2021-00347, Oct. 6, 2021.
[cited by applicant]
Deutetrabenazine (Austedo) Clinical Pharmacology and Biopharmaceutical Review (Apr. 2016)—Part 1 of 3, Exhibit 2095 for Inter Partes Review No. IPR2021-00347, Oct. 6, 2021.
[cited by applicant]
Deutetrabenazine (Austedo) Clinical Pharmacology and Biopharmaceutical Review (Apr. 2016)—Part 2 of 3, Exhibit 2095 for Inter Partes Review No. IPR2021-00347, Oct. 6, 2021.
[cited by applicant]
Deutetrabenazine (Austedo) Clinical Pharmacology and Biopharmaceutical Review (Apr. 2016)—Part 3 of 3, Exhibit 2095 for Inter Partes Review No. IPR2021-00347, Oct. 6, 2021.
[cited by applicant]
CAS Registry Entry for Tramiprosate, Exhibit 2030 for Inter Partes Review No. IPR2021-00347, Oct. 6, 2021.
[cited by applicant]
CAS Registry Entry for D2-tramiprosate, Exhibit 2031 for Inter Partes Review No. IPR2021-00347, Oct. 6, 2021.
[cited by applicant]
CAS Registry Entry for Val-APS, Exhibit 2032 for Inter Partes Review No. IPR2021-00347, Oct. 6, 2021.
[cited by applicant]
Exhibit 2026 for Inter Partes Review, IDS considered on Jan. 2, 2019 and Jul. 9, 2018 in U.S. Appl. No. 15/476,255 now U.S. Pat. No. 10,472,323.
[cited by applicant]
Exhibit 2041 for Inter Partes Review, Videoconference deposition of Peter Guengerich, Ph. D., Sep. 28, 2021.
[cited by applicant]
Exhibit 2066 for Inter Partes Review, U.S. Appl. No. 15/476,255, filed Mar. 31, 2017.
[cited by applicant]
Exhibit 2098 for Inter Partes Review, Teva Pharmaceutical Inndustries Ltd., Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, May 2016.
[cited by applicant]
Exhibit 3001 for Inter Partes Review, Aisen P. S. et al., Tramiprosate in mild-to-moderate Alzheimer's disease—a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study), Arch Med Sci 2011, 7…
[cited by applicant]
Exhibit 1043 for Inter Partes Review, Harbeson S.L et al., Deuterium Medicinal Chemistry: A New Approach to Drug Discovery and Development, Medchem News No. 2, May 2014.
[cited by applicant]
Exhibit 1044 for Inter Partes Review, Ma Y. et al., Synthesis of Homotaurine and 1-substituted Homotaurines from a, b-Unsaturated Nitriles, Synthesis 2012, 44, 2225-2230, Jun. 13, 2012.
[cited by applicant]
Exhibit 1045 for Inter Partes Review, CAS Reaction Search, Dec. 6, 2021.
[cited by applicant]
Exhibit 1047 for Inter Partes Review, Errata to Transcript of Sep. 28, 2021 deposition of F. Peter Guengerich.
[cited by applicant]
Exhibit 1048 for Inter Partes Review, Deposition of Jonathan L. Sessler, Ph.D., Dec. 8, 2021.
[cited by applicant]
Exhibit 1050 for Inter Partes Review, Manzano S. et al., A Review on Tramiprosate (Homotaurine) in Alzheimer's Disease and Other Neurocognitive Disorders, Frontiers in Neurology, vol. 11, Article 614, Jul. 2020.
[cited by applicant]
Exhibit 1051 for Inter Partes Review, Martorana A. et al., Homotaurine induces measurable changes of short latency afferent inhibition in a group of mild cognitive impairment individuals, Frontiers in Aging Neuroscience…
[cited by applicant]
Exhibit 1052 for Inter Partes Review, Spalletta G. et al., Homotaurine Effects on Hippocampal Volume Loss and Episodic Memoty in Amnestic Mild Cognitive Impairment, Journal of Alzheimer's Disease 50 (2016) 807-816.
[cited by applicant]
Exhibit 1053 for Inter Partes Review, Bossu P. et al., Anti-inflammatory Effects of Homotaurine in Patients with Amnestic Mild Cognitive Impairment, Frontiers in Aging Neuroscience, vol. 10, Article 285, Nov. 2018.
[cited by applicant]
Exhibit 1054 for Inter Partes Review, Abushakra S. et al., Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential, The Journal of Prevention …
[cited by applicant]
Exhibit 1055 for Inter Partes Review, Sabbagh M.N., Clinical Effects of Oral Tramiprosate in APOE4/4 Homozygous Patents with Mild Alzheimer's Disease Suggest Disease Modification, The Journal of Prevention of Alzheimer'…
[cited by applicant]
Exhibit 1058 for Inter Partes Review, Azzi M. et al., Involvement of both Gaba-Dependant and -Independant Pathways in Tramiprosate Neuroprotective Effects Against Amyloid-Beta Toxicity, Neurodegenerative Dis 2007;4(supp…
[cited by applicant]
Exhibit 1059 for Inter Partes Review, Janssens de Varebeke P. et al., Formation of the neurotransmitter glycine from the anticonvulsant Milacemide is mediated by brain monoamine oxidase B, Journal of Neirochemistry, 198…
[cited by applicant]
Exhibit 1060 for the Inter Partes Review, Matsukawa M. et al., A screening system of prodrugd selective for MAO-A or MAO-B, NeuroToxicology 25, 293-302, 2004.
[cited by applicant]
Exhibit 1061 for the Inter Partes Review, Fieser L.F. et al., Reagents for Organic Synthesis, 1967.
[cited by applicant]
Exhibit 1062 for the Inter Partes Review, Wade L.G. Jr., Organic Chemistry, 5th edition, 2003.
[cited by applicant]
Exhibit 1063 for the Inter Partes Review, March J., Advance Organic Chemistry, “Reactions, mechanisms, and structure”, 3rd edition, 1985.
[cited by applicant]
Exhibit 1064 for the Inter Partes Review, Mullard, A. Deuterated drugs draw heavier backing, Nature Reviews—Drug Discovery, vol. 15, Apr. 2016.
[cited by applicant]
Exhibit 1065 for the Inter Partes Review, Teva Annonces Positive Top-Line Data from Second Phase III Study of SD-809 in Tardive Dyskinesia (TD), Sep. 22, 2016.
[cited by applicant]
Exhibit 1066 for the Inter Partes Review, Guengerich, F.P et al., Methylene Oxidation of Alkyl Sulfates by Cytochrome P450BM-3 and a Role for Conformational Selection in Substrate Recognition, American Chemical Societe,…
[cited by applicant]
Exhibit 1067 for the Inter Partes Review, De Strooper, B., Lessons from a Failed y-Secretase Alzheimer Trial, Cell 159, Nov. 6, 2014.
[cited by applicant]
Exhibit 1068 for the Inter Partes Review, Sharma R. et al., Deuterium Isotope Effects on Drug Pharmacokinetics. I. System-Dependent Effects of Specific Deuteration with Aldehyde Oxidase Cleared Drugs, The American Socie…
[cited by applicant]
Exhibit 1069 for the Inter Partes Review, Deposition of S. David Kimball, Ph.D., Feb. 24, 2022.
[cited by applicant]
Exhibit 1071 for the Inter Partes Review, Kurtz K.A. et al., pH and Secondary Kinetic Isotope Effects on the Reaction of D-Amino Acid Oxidase with Nitroalkane Anions: Evidence for Direct Attack on the Flavin by Carbanio…
[cited by applicant]
Exhibit 1072 for the Inter Partes Review, Walsh, C. Enzymatic Reaction Mechanisms, 1977.
[cited by applicant]
Exhibit 1073 for the Inter Partes Review, Cook P.F. et al., Enzyme Kinetics and Mechanism, 2007.
[cited by applicant]
Paper No. 19 for the Inter Partes Review, Patent owner's contigent motion to amend pursuant to 37 CFR 42.121, Oct. 6, 2021.
[cited by applicant]
Paper No. 34 for the Inter Partes Review, Petitioner's reply to Patent owner response, Mar. 3, 2022.
[cited by applicant]
Paper No. 35 for the Inter Partes Review, Petitioner's opposition to contingent motion to amend, Mar. 3, 2022.
[cited by applicant]
Shuangchan et al., Tramiprosate protects neurons against ischemic stroke by disrupting the interaction between PSD95 and nNOS, Neuropharmacology, vol. 83, p. 107-117, Apr. 24, 2014.
[cited by applicant]